These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26961515)

  • 1. Promising therapeutic agents for the treatment of Parkinson's disease.
    Majláth Z; Török N; Toldi J; Vécsei L
    Expert Opin Biol Ther; 2016 Jun; 16(6):787-99. PubMed ID: 26961515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and emerging medical therapies in Parkinson's disease.
    Lotia M; Jankovic J
    Expert Opin Pharmacother; 2016; 17(7):895-909. PubMed ID: 26830844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.
    Ramirez-Zamora A; Molho E
    Expert Rev Neurother; 2014 Jan; 14(1):93-103. PubMed ID: 24328720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upcoming treatments in Parkinson's disease, including gene therapy.
    Rodnitzky RL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S37-40. PubMed ID: 22166449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies in the pharmacological treatment of Parkinson's disease.
    Korczyn AD; Nussbaum M
    Drugs; 2002; 62(5):775-86. PubMed ID: 11929331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2017 Oct; 18(14):1457-1465. PubMed ID: 28847181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
    Perez-Lloret S; Merello M
    Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future treatments for Parkinson's disease: surfing the PD pipeline.
    Hauser RA
    Int J Neurosci; 2011; 121 Suppl 2():53-62. PubMed ID: 22035030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Available and emerging treatments for Parkinson's disease: a review.
    Hickey P; Stacy M
    Drug Des Devel Ther; 2011; 5():241-54. PubMed ID: 21607020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?
    Torti M; Vacca L; Stocchi F
    Expert Opin Pharmacother; 2018 Nov; 19(16):1821-1828. PubMed ID: 30232916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for levodopa-induced dyskinesia.
    Al Dakheel A; Beaulieu-Boire I; Fox SH
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.